B. Riley Securities to Host Precision Oncology & Radiopharma Investor Conference in New York on February 28, 2025
B. Riley Securities has announced its upcoming Precision Oncology & Radiopharma Investor Conference, scheduled for February 28, 2025, in New York. The one-day event will showcase over 30 companies focused on next-generation targeted oncology and radiopharmaceutical therapeutics and diagnostics.
The conference will feature research analyst-moderated panels discussing healthcare policy disruptions, radiopharma value chain developments, antibody drug conjugates, T-cell engagers, and synthetic lethality approaches. These emerging modalities have been significant targets in recent pharmaceutical acquisitions.
According to Andy Moore, CEO of B. Riley Securities, the conference brings together industry leaders developing breakthrough therapies, offering investors opportunities to participate in healthcare advancement. The event format includes panels, presentations, fireside chats, and roundtables, with attendance being invitation-only. Interested parties can register by emailing BRSHealthcareEvents@brileyfin.com.
B. Riley Securities ha annunciato la sua prossima Conferenza per Investitori sulla Oncologia di Precisione e Radioterapia, programmata per il 28 febbraio 2025, a New York. L'evento di un giorno presenterà oltre 30 aziende focalizzate su terapie e diagnostica oncologica e radioterapica di nuova generazione.
La conferenza includerà pannelli moderati da analisti di ricerca che discuteranno delle interruzioni nella politica sanitaria, degli sviluppi nella catena del valore della radioterapia, dei coniugati di farmaci ad anticorpi, degli attivatori delle cellule T e degli approcci di letalità sintetica. Queste modalità emergenti sono state obiettivi significativi nelle recenti acquisizioni farmaceutiche.
Secondo Andy Moore, CEO di B. Riley Securities, la conferenza riunisce leader del settore che sviluppano terapie innovative, offrendo agli investitori opportunità di partecipare all'avanzamento della sanità. Il formato dell'evento include pannelli, presentazioni, conversazioni informali e tavole rotonde, con partecipazione su invito. Le parti interessate possono registrarsi inviando un'email a BRSHealthcareEvents@brileyfin.com.
B. Riley Securities ha anunciado su próxima Conferencia de Inversores en Oncología de Precisión y Radioterapia, programada para el 28 de febrero de 2025, en Nueva York. El evento de un día presentará más de 30 empresas enfocadas en terapias y diagnósticos oncológicos y radioterapéuticos de próxima generación.
La conferencia contará con paneles moderados por analistas de investigación que discutirán interrupciones en la política de salud, desarrollos en la cadena de valor de la radioterapia, conjugados de fármacos anticuerpos, activadores de células T y enfoques de letalidad sintética. Estas modalidades emergentes han sido objetivos significativos en adquisiciones farmacéuticas recientes.
Según Andy Moore, CEO de B. Riley Securities, la conferencia reúne a líderes de la industria que desarrollan terapias innovadoras, ofreciendo a los inversores oportunidades para participar en el avance de la salud. El formato del evento incluye paneles, presentaciones, charlas informales y mesas redondas, con asistencia solo por invitación. Las partes interesadas pueden registrarse enviando un correo electrónico a BRSHealthcareEvents@brileyfin.com.
B. Riley Securities는 2025년 2월 28일 뉴욕에서 열릴 예정인 정밀 종양학 및 방사선 제약 투자자 회의를 발표했습니다. 하루 동안 진행되는 이 행사에서는 차세대 표적 종양학 및 방사선 치료제와 진단에 초점을 맞춘 30개 이상의 기업이 소개될 예정입니다.
회의에서는 의료 정책의 혼란, 방사선 제약 가치 사슬 개발, 항체 약물 접합체, T세포 결합제, 합성 치사 접근 방식에 대해 논의하는 연구 분석가 주재 패널이 포함됩니다. 이러한 신흥 방식은 최근 제약 인수에서 중요한 목표가 되어왔습니다.
Andy Moore B. Riley Securities CEO에 따르면, 이 회의는 혁신적인 치료제를 개발하는 업계 리더들을 한자리에 모아 투자자들에게 의료 발전에 참여할 기회를 제공합니다. 행사 형식에는 패널, 발표, 화로 대화 및 원탁 회의가 포함되며, 참석자는 초대받은 사람만 가능합니다. 관심 있는 분들은 BRSHealthcareEvents@brileyfin.com으로 이메일을 보내 등록할 수 있습니다.
B. Riley Securities a annoncé sa prochaine Conférence des Investisseurs en Oncologie de Précision et Radiopharmacie, prévue pour le 28 février 2025, à New York. Cet événement d'une journée présentera plus de 30 entreprises axées sur les thérapies et diagnostics en oncologie ciblée et radiopharmaceutique de nouvelle génération.
La conférence comportera des panels modérés par des analystes de recherche discutant des disruptions de la politique de santé, des développements de la chaîne de valeur radiopharmaceutique, des conjugués de médicaments anticorps, des engageurs de cellules T et des approches de létalité synthétique. Ces modalités émergentes ont été des cibles significatives dans les récentes acquisitions pharmaceutiques.
Selon Andy Moore, PDG de B. Riley Securities, la conférence rassemble des leaders de l'industrie développant des thérapies révolutionnaires, offrant aux investisseurs des opportunités de participer à l'avancement des soins de santé. Le format de l'événement comprend des panels, des présentations, des discussions informelles et des tables rondes, avec une participation sur invitation uniquement. Les parties intéressées peuvent s'inscrire en envoyant un e-mail à BRSHealthcareEvents@brileyfin.com.
B. Riley Securities hat seine bevorstehende Konferenz für Investoren in Präzisionsonkologie und Radiopharma angekündigt, die für den 28. Februar 2025 in New York geplant ist. Die eintägige Veranstaltung wird über 30 Unternehmen präsentieren, die sich auf Therapien und Diagnosen in der zielgerichteten Onkologie und Radiopharmazeutika der nächsten Generation konzentrieren.
Die Konferenz wird von Forschungsanalysten moderierte Panels umfassen, die über Störungen in der Gesundheitspolitik, Entwicklungen in der Wertschöpfungskette der Radiopharma, Antikörper-Wirkstoff-Konjugate, T-Zell-Engager und Ansätze zur synthetischen Letalität diskutieren. Diese aufkommenden Modalitäten waren bedeutende Ziele in den letzten pharmazeutischen Übernahmen.
Laut Andy Moore, CEO von B. Riley Securities, bringt die Konferenz Branchenführer zusammen, die bahnbrechende Therapien entwickeln und Investoren die Möglichkeit bieten, am Fortschritt im Gesundheitswesen teilzunehmen. Das Veranstaltungsformat umfasst Panels, Präsentationen, Kamin-Gespräche und Runden Tische, die Teilnahme erfolgt nur auf Einladung. Interessierte können sich per E-Mail an BRSHealthcareEvents@brileyfin.com registrieren.
- None.
- None.
This one-day conference will feature more than 30 institutionally relevant companies developing and commercializing next-gen targeted oncology and radiopharmaceutical therapeutics and diagnostics. In addition to investor discussions, B. Riley Equity Research Analysts will be moderating panels covering topics including recent disruptions to healthcare policy, the evolving radiopharma value chain, antibody drug conjugates and T-cell engagers, and novel approaches in synthetic lethality.
The emerging modalities being developed and commercialized by the attending companies have represented an outsized proportion of recent pharma acquisitions. As the field evolves, this conference is bringing together industry leaders for early insight into breakthrough therapies.
Andy Moore, CEO of B. Riley Securities, commented: "We're excited to bring together a curated selection of companies at the forefront of delivering life-saving and critical therapeutic and imaging modalities. Their pursuits are ground-breaking and create an opportunity for investors to participate in the next wave of advancement in healthcare."
The conference will feature a comprehensive schedule, including research analyst-moderated panels, presentations, fireside chats and roundtables.
Participation in the conference is by invitation only. If you are interested in registering for the event, please email BRSHealthcareEvents@brileyfin.com
B. Riley Securities, Inc.
B. Riley has served as a preeminent middle market brokerage and investment banking firm for over 25 years. We provide a full suite of investment banking and capital markets services to companies, financial sponsors, and institutional investors across all industry verticals. Investment banking services include initial, secondary and follow-on offerings, institutional private placements, merger and acquisition (M&A) advisory, SPACs, corporate restructuring and recapitalization. Widely recognized for our thematic proprietary equity research, clients benefit from B. Riley's extensive network, industry expertise, and proven execution capabilities of our end-to-end financial services platform. Please see disclosures about B. Riley Securities Research here. The firm is a subsidiary of B. Riley Financial (Nasdaq: RILY). For more information, visit www.brileysecurities.com.
Contacts
press@brileyfin.com
View original content:https://www.prnewswire.com/news-releases/b-riley-securities-to-host-precision-oncology--radiopharma-investor-conference-in-new-york-on-february-28-2025-302382323.html
SOURCE B. Riley Financial
FAQ
When and where is B. Riley Securities hosting its Precision Oncology Conference in 2025?
How many companies will be presenting at B. Riley's 2025 Oncology Conference?
What key topics will be discussed at B. Riley's 2025 Radiopharma Conference?
How can investors register for B. Riley's 2025 Precision Oncology Conference?
What types of sessions will be featured at B. Riley's 2025 healthcare conference?
